The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 29 April 2026•Updated 29 April 2026•

1 min read

AbbVie Beats Quarterly Estimates on Strong Demand for New Immunology Drugs

Key Facts

1AbbVie reported quarterly revenue and profit exceeding analyst expectations, driven by strong demand for Skyrizi and Rinvoq.

2Global Botox Therapeutic sales exceeded $1 billion in quarterly sales for the first time within the neuroscience portfolio.

about 1 month ago

Version History

2 additional sources confirmed this story

Version 3about 1 month ago

What changed: Added specific Q1 2026 revenue figures ($15.00B vs $14.72B estimate) and confirmed the ABBV ticker symbol.

Version 2about 1 month ago

What changed: Confirmed the specific fiscal period as the first quarter and validated that revenue growth was driven by the immunology and neuroscience segments.

Version 1about 1 month ago

What changed: The story was updated to include the company's upward revision of its 2026 annual earnings guidance with specific per-share targets.

AbbVie Inc. (NYSE: ABBV) reported first-quarter 2026 sales of $15.00 billion, exceeding the consensus estimate of $14.72 billion. The robust performance of Skyrizi and Rinvoq played a crucial role in offsetting the revenue decline of Humira due to biosimilar competition. Notably, global sales for Botox Therapeutic surpassed the $1 billion mark in a single quarter for the first time, highlighting the strength of the neuroscience segment. Following these results, the company raised its 2026 annual earnings guidance to a range of $14.08 to $14.28 per share. This upward revision signals long-term stability and management's confidence in the firm's strategic growth trajectory. Investors remain focused on AbbVie's ability to maintain this momentum during its ongoing portfolio rotation toward next-generation treatments.